Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

Marie Skłodowska-Curie Action · Running

EVEREST Extracellular Vesicle Research Exchanges for Advanced Biomarkers and Therapeutics

Coordinator
University College Dublin, National University of Ireland, Dublin, Ireland
Runs
1 January 2025 to 31 December 2028
Status
Running
EU funding
€1.3m
Total cost
—
Partners
22 organisations in 12 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101183034

What the project is doing

In the project's own words, from its summary on CORDIS.

The EVEREST project is a pioneering consortium in Extracellular Vesicle (EVs) research, bringing together 22 institutions from 11 countries, including 3 UK partners. This interdisciplinary consortium is distinguished by an ambitious plan for over 285 months of staff exchanges, engaging at least 81 fellows. Research-Innovation programme is structured into four pivotal work packages:1.Combining Expertise and Resources for Advancing Standardised Characterisation and Isolation of EVs: Focused on harmonizing methods for EV isolation across diverse tissues and samples, enhancing the consistency and reliability of EV research.2.Jointly Investigating EVs in Health or Disease, and Enhancing Translational Biomarker Discovery: Concentrated on exploring the roles of EVs in various health conditions and diseases, with a particular emphasis on identifying and validating new biomarkers for diagnostic and prognostic applications.3.Uniting Capacities, Advancing EV-Based Therapeutics or Drug Delivery: Dedicated to developing innovative EV-based treatments and drug delivery mechanisms, targeting key health challenges like cancer and cardiovascular diseases.4.Catalysing commercial development of EV-based technologies: Aiming to bridge the gap between research and practical application, this work package focuses on preparing EV-based solutions for large-scale production and market introduction.

At its core, EVEREST is committed to significantly enhancing the capabilities of participating institutions and fostering career advancement for involved fellows. By positioning EVs as critical tools for biomarker discovery and therapeutic applications, the project aims to make substantial contributions to personalized medicine and improved health outcomes, ultimately translating research breakthroughs into clinical practice.

Topics

Who is involved

OrganisationCityCountryRole
University College Dublin, National University of Ireland, DublinDublinIrelandCoordinator
Fox Biosystems NVDiepenbeekBelgiumAssociatedpartner
Justus-Liebig-Universitaet GiessenGiessenGermanyParticipant
Region HovedstadenHillerodDenmarkParticipant
De Rotos Y Descosidos ScValladolidSpainParticipant
Fundacion Publica Andaluza Progreso Y Salud M.p.SevillaSpainParticipant
Universidad De VigoVigo PontevedraSpainParticipant
Xenopat SLHospitalet De LlobregatSpainParticipant
Pharmahungary 2000 Kiserletes Es Klinikai Kutatasfejlesztesi Korlatoltfelelossegu TarsasagSzegedHungaryParticipant
Siriusxt LimitedDublinIrelandParticipant
South East Technological UniversityWaterfordIrelandParticipant
The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near DublinDublinIrelandParticipant
Valstybinis Moksliniu Tyrimu Institutas Inovatyvios Medicinos CentrasVilniusLithuaniaParticipant
Luxembourg Institute of Science and TechnologyEsch Sur AlzetteLuxembourgParticipant
Universidade Nova De LisboaLisboaPortugalParticipant
Acousort ABLundSwedenParticipant
Bioreperia ABLinkopingSwedenParticipant
Linkopings UniversitetLinkopingSwedenParticipant
Univerzita Komenskeho V BratislaveBratislava 1SlovakiaParticipant
Mursla LimitedLondonUnited KingdomAssociatedpartner
The Queen's University of BelfastBelfastUnited KingdomAssociatedpartner
Vesiculab LtdNottinghamUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI